Protocol Status: PUBLISHED
Protocol:
Version: 2026.01
Effective Date:
Last Reviewed:
Medical Director Approval:
Clinical Note: This content reflects current GCEMS clinical guidelines as of the dates listed above. If content appears inconsistent with current policy, use the most recent approved guideline and notify leadership for correction.

Shock/Allergic Reaction

(BLS Only)

 

History:

 

  • Onset and location
  • Insect sting/bite
  • Food allergy/exposure
  • Medication allergy/exposure
  • New clothing, soap, detergent
  • Past history of reactions
  • Past medical history
  • Medication history
    • Antipsychotics
    • Antiemetics
    • Ace inhibitors

 

Significant Findings:

 

  • Itching/hives
  • Respiratory distress
  • Chest/throat constriction
  • Difficulty swallowing
  • Hypotension/shock
  • Nausea
  • Vomiting

 

Differential:

 

  • Urticaria (rash only)
  • Anaphylaxis (systemic effect)
  • Shock (vascular effect)
  • Angioedema (drug induced)
  • Aspiration/airway obstruction
  • Vasovagal event
  • Asthma
  • COPD
  • CHF

 

DO NOT use this order if chest pain is thought to be cardiac in origin

 

 

Wheezing, airway involvement, hypotension, difficulty swallowing, swollen tongue or lips ?

 

  • Yes

 

    • Epinephrine Auto-Injector
        • or
    • Epinephrine Anaphylaxis Kit
      • Adults: 1:1,000 0.3 mg IM
      • Pediatrics: 0.15 mg IM;

 

 

    • If conditions worsens repeat
    • Epinephrine Auto-Injector or
    • Epinephrine Anaphylaxis Kit
      • Adults: 0.3 mg;
      • Pediatrics: 0.15 mg

 

 

  • Anaphylaxis Epinephrine Kit should include the following:
    • 1 - Tuberculin syringe 1 mL
    • 2 - 20-22 gauge 1” – 1½” needles
    • 2 - Alcohol Preps
    • 1 - Epinephrine Ampule or Vial 1:1,000 – 1mg/1mL

 

 

PEARLS:

 

  • Patients 15 to 30 kg: 0.15 mg or 0.15 mL. Injection site for IM injection should be the lateral thigh.
  • Patients great than or equal to 30 kg: 0.3 mg or 0.3 mL.
  • Contact Medical Control prior to administering Epinephrine in patients who are >50 years of age, have a history of cardiac disease, or if the patients heart rate is >150.
  • The dosages follow the existing commercial Epinephrine Auto-Injector Dosages.